Walvax Biotechnology's (SHE:300142) unit, Yuxi Walvax Biotechnology, received a drug registration certificate from China's National Medical Products Administration for the novel coronavirus mRNA vaccine, according to a Shenzhen bourse filing on Friday.
The vaccine has a specification of 0.15 milligrams per vial.
The vaccine producer's shares rose 1% during the midday trade.